专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL234483A Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same 未知
公开(公告)号：IL234483A
公开(公告)日：2019-06-30
申请号：IL23448314
申请日：2014-09-04
申请人： YEDA RES & DEV , TAL ILANI , DEBORAH FASS , IRIS GROSSMAN , ASSAF ALON
发明人： TAL ILANI , DEBORAH FASS , IRIS GROSSMAN , ASSAF ALON
IPC分类号： A61K39/395 , A61P35/00 , C07K16/40
摘要： The present invention relates to a therapeutically effective amount of an antibody which inhibits QSOX1 activity, for use in treating a disease or condition associated with fibrosis.

2. 发明公开

US20240223342A1 CHOOSING A CHANNEL FOR PROXIMITY SENSING IN A USER DEVICE 审中-公开
公开(公告)号：US20240223342A1
公开(公告)日：2024-07-04
申请号：US18090803
申请日：2022-12-29
申请人： Assaf Gurevitz , Tal Ilani , Gadi Shor , Uri Perlmutter , Itamar Borochow , Maxim Stepanov
发明人： Assaf Gurevitz , Tal Ilani , Gadi Shor , Uri Perlmutter , Itamar Borochow , Maxim Stepanov
IPC分类号： H04L5/00 , H04B7/06 , H04W72/0453
CPC分类号： H04L5/0062 , H04B7/0691 , H04W72/0453
摘要： Described herein is an apparatus having at least two antennas to communicate over multiple communication channels. The apparatus can further include processing circuitry coupled to the at least two antennas to measure isolation in the communication channels while the communication channels are operating in a radar mode to select a channel having highest isolation among the communication channels. The processing circuitry can further perform radar detection over the channel having highest isolation. Other systems and methods are described.

3. 发明申请

US20050158715A1 Method for the diagnosis and follow up of schizophrenia and other mental and neurodegenerative disorders 审中-公开
标题翻译：诊断和跟进精神分裂症和其他精神和神经退行性疾病的方法
公开(公告)号：US20050158715A1
公开(公告)日：2005-07-21
申请号：US10344862
申请日：2001-08-15
申请人： Sara Fuchs , Tal Ilani , Orly Perl
发明人： Sara Fuchs , Tal Ilani , Orly Perl
IPC分类号： C12Q1/68 , C12Q1/6883 , G06F19/00 , G01N33/48 , G01N33/50
CPC分类号： C12Q1/6883 , C12Q2600/156 , Y02A90/22 , Y02A90/26
摘要： A method for the diagnosis and follow up of a mental disorder or of a neurodegenerative disorder in an individual, comprises: (i) measuring mRNA of D3 dopamine receptor and/or of α7 nicotinic acetylcholine receptor (α7 AChR) and of a control gene in peripheral blood lymphocytes (PBLs) of said individual and of at least one healthy control individual; (ii) calculating the ratio between the D3 dopamine receptor mRNA and the control gene mRNA and/or the ratio between α7 AChR mRNA and the control gene mRNA for each individual; and (iii) evaluating the ratio between the ratios obtained in (ii) for the tested individual and for the at least one healthy control individual, wherein an increase in the D3 dopamine receptor mRNA and/or a decrease in the α7 AChR mRNA in the tested individual in comparison to healthy individuals, indicate that said tested individual has a high likelihood of having said mental disorder or neurodegenerative disorder, wherein said increase in the D3 dopamine receptor mRNA and/or decrease in the α7 AChR mRNA in the tested individual is correlated to said mental disorder or neurodegenerative disorder. When the mental disorder is schizophrenia, an increase of above 1.6 fold in the D3 dopamine receptor mRNA and/or a decrease of more than 20% in the α7 AChR mRNA in the tested individual in comparison to healthy individuals, indicate that said tested individual has a high likelihood of having schizophrenia.
摘要翻译：用于诊断和跟踪个体精神障碍或神经变性疾病的方法包括：（i）测量D 3 N多巴胺受体和/或α7烟碱乙酰胆碱受体（α7）的mRNA AChR）和所述个体和至少一个健康对照个体的外周血淋巴细胞（PBL）中的对照基因; （ii）计算每个个体的D 3 N多巴胺受体mRNA和对照基因mRNA之间的比例和/或α7AChRmRNA与对照基因mRNA之间的比率; 和（iii）评估测试个体和至少一个健康对照个体在（ii）中获得的比例之间的比例，其中D 3 N多巴胺受体mRNA和/或与健康个体相比，测试个体中α7AChRmRNA的减少表明所述测试个体具有很高的患有精神障碍或神经变性障碍的可能性，其中所述D 3多巴胺受体的增加测试个体中α7AChRmRNA的mRNA和/或降低与所述精神障碍或神经变性疾病相关。当精神障碍为精神分裂症时，与健康人相比，D 3 N 3多巴胺受体mRNA的增加高于1.6倍，并且测试个体的α7AChRmRNA的降低超过20％个体表明，所述被测试的个体很可能患有精神分裂症。

4. 发明授权

US07939262B2 Method for the diagnosis of schizophrenia 失效
标题翻译：精神分裂症诊断方法
公开(公告)号：US07939262B2
公开(公告)日：2011-05-10
申请号：US12490195
申请日：2009-06-23
申请人： Sara Fuchs , Tal Ilani , Orly Perl
发明人： Sara Fuchs , Tal Ilani , Orly Perl
IPC分类号： C12Q1/68 , C12P19/34 , C07H21/02
CPC分类号： C12Q1/6883 , C12Q2600/156 , Y02A90/22 , Y02A90/26
摘要： A method for the diagnosis of schizophrenia in an individual comprises: (i) measuring mRNA of either D3 dopamine receptor or α7 nicotinic acetylcholine receptor (α7 AChR), and of a control gene in peripheral blood lymphocytes (PBLs) of the individual and of at least one healthy control individual; (ii) calculating the ratio between the receptor mRNA and the control gene mRNA for each individual; and (iii) evaluating the ratio between the ratios obtained in (ii) for the tested individual and for the at least one healthy control individual, wherein (a) an increase in the D3 dopamine receptor mRNA or a decrease in the α7 AChR in the tested individual in comparison to healthy individuals, indicates that said tested individual has a higher likelihood of having schizophrenia than the healthy controls.
摘要翻译：用于诊断个体中精神分裂症的方法包括：（i）测量D3多巴胺受体或α7烟碱乙酰胆碱受体（α7AChR）的mRNA和个体的外周血淋巴细胞（PBL）中的对照基因至少一个健康控制个体; （ii）计算每个个体的受体mRNA和对照基因mRNA之间的比例; 和（iii）评估测试个体和至少一个健康对照个体在（ii）中获得的比例之间的比例，其中（a）D3多巴胺受体mRNA的增加或α7AChR的降低测试个体与健康个体相比，表明所测试的个体比健康对照具有更高的精神分裂症的可能性。

5. 发明申请

US20100041043A1 METHOD FOR THE DIAGNOSIS AND FOLLOW-UP OF SCHIZOPHRENIA AND OTHER MENTAL AND NEUROLOGICAL DISORDERS 失效
标题翻译：方法和其他精神和神经疾病的诊断和后续方法
公开(公告)号：US20100041043A1
公开(公告)日：2010-02-18
申请号：US12490195
申请日：2009-06-23
申请人： Sara Fuchs , Tal Ilani , Orly Perl
发明人： Sara Fuchs , Tal Ilani , Orly Perl
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156 , Y02A90/22 , Y02A90/26
摘要： A method for the diagnosis and follow up of a mental disorder or of a neurodegenerative disorder in an individual, comprises: (i) measuring mRNA of D3 dopamine receptor and/or of α7 nicotinic acetylcholine receptor (α7 AChR) and of a control gene in peripheral blood lymphocytes (PBLs) of said individual and of at least one healthy control individual; (ii) calculating the ratio between the D3 dopamine receptor mRNA and the control gene mRNA and/or the ratio between α7 AChR mRNA and the control gene mRNA for each individual; and (iii) evaluating the ratio between the ratios obtained in (ii) for the tested individual and for the at least one healthy control individual, wherein an increase in the D3 dopamine receptor mRNA and/or a decrease in the α7 AChR mRNA in the tested individual in comparison to healthy individuals, indicate that said tested individual has a high likelihood of having said mental disorder or neurodegenerative disorder, wherein said increase in the D3 dopamine receptor mRNA and/or decrease in the α7 AChR mRNA in the tested individual is correlated to said mental disorder or neurodegenerative disorder. When the mental disorder is schizophrenia, an increase of above 1.6 fold in the D3 dopamine receptor mRNA and/or a decrease of more than 20% in the α7 AChR mRNA in the tested individual in comparison to healthy individuals, indicate that said tested individual has a high likelihood of having schizophrenia.
摘要翻译：用于诊断和跟踪个体精神障碍或神经变性疾病的方法包括：（i）测量D3多巴胺受体和/或α7烟碱乙酰胆碱受体（α7AChR）的mRNA和对照基因的mRNA 所述个体和至少一个健康对照个体的外周血淋巴细胞（PBL）; （ii）计算D3多巴胺受体mRNA和对照基因mRNA之间的比例和/或每个个体的α7AChRmRNA和对照基因mRNA之间的比例; 和（iii）评估测试个体和至少一个健康对照个体在（ii）中获得的比例之间的比例，其中D3多巴胺受体mRNA的增加和/或α7AChRmRNA的降低测试个体与健康个体相比，表明所述被测试的个体很可能患有精神障碍或神经变性疾病，其中所述D3多巴胺受体mRNA的增加和/或所测试个体中α7AChRmRNA的降低相关涉及精神障碍或神经退行性疾病。当精神障碍为精神分裂症时，与健康个体相比，D3多巴胺受体mRNA的增加高于1.6倍，和/或与所测试的个体相比，α7AChRmRNA的降低超过20％，表明所测试的个体具有精神分裂症的可能性很大。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式